Expectations were for roughly $62.8 million of revenue and about $1.92–$2.00 of adjusted EPS; Ligand cleared both. Second-quarter revenue was $63.7 million and adjusted diluted EPS was $2.37, versus year-ago figures of $47.6 million and $1.60, respectively. That makes the revenue beat modest, but the EPS beat meaningful; published estimates clustered near those levels.
| Metric | Q2 2026 | Q2 2025 | Versus expectation |
|---|---|---|---|
| Total revenues and income | $63.7M | $47.6M | Above roughly $62.8M consensus |
| Royalties | $48.0M | $36.4M | 32% year over year (Financial Statements) |
| Adjusted net income | $50.8M | $32.0M | 59% year over year (Adjusted Net Income reconciliation) |
| Adjusted diluted EPS | $2.37 | $1.60 | Above roughly $1.92–$2.00 consensus |
| Cash, cash equivalents and short-term investments | $1.36B | $733.5M at Dec. 31, 2025 | Up after debt financing (Balance Sheet) |
| 2026 adjusted core EPS guidance | $9.00–$9.50 | Previously $8.50–$9.50 | Low end raised by $0.50 (Financial Outlook) |
The underlying earnings quality was better than the headline GAAP profit suggests. Royalty revenue, the core recurring engine, rose 32% to $48.0 million, led by Filspari, Zelsuvmi and Ohtuvayre; Filspari’s partner also reported 96% year-over-year product-sales growth, while Ohtuvayre and Capvaxive continued to scale. Captisol revenue slipped to $8.0 million, and the quarter’s $35.7 million gain on Pelthos-related investments was non-cash, but adjusted EPS still reached $2.37 after excluding that volatility (Financial Highlights; Partner Product Updates; Adjusted Net Income reconciliation).
The guidance move is the clearest incremental positive. Ligand reaffirmed 2026 revenue guidance of $270 million–$310 million but raised the low end of adjusted core EPS guidance to $9.00 from $8.50, citing stronger XOMA cost synergies, additional interest income from the 0% convertible notes and the share repurchase (Financial Outlook). Because the revenue range was unchanged, the upgrade is primarily a profitability and capital-structure benefit rather than a demand reset.
XOMA now moves from transaction promise to operating contribution, but the financing adds leverage. The acquisition closed on schedule and is expected to contribute roughly $0.50 per share to 2026 adjusted EPS and $1.50 in 2027, while more than doubling Ligand’s royalty portfolio to over 200 assets (Business Update). At the same time, convertible senior notes rose to $1.13 billion from $446.2 million at year-end, so the stronger cash balance reflects financing proceeds rather than operating cash generation alone (Balance Sheet). The net read is positive: a clear EPS beat, a higher earnings floor and improving royalty momentum, tempered by greater debt and continued reliance on partner execution.
Read the original 8-K on SEC EDGAR ↗